SeaCrest Wealth Management’s Regenxbio RGNX Stock Holding History

SeaCrest Wealth Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-835	Closed	-$21K	–	1312
2022 Q2	$21K	Buy	+835	New	+$20.9K	﹤0.01%	1468
2019 Q2	–	Sell	-50	Closed	-$3K	–	1562
2019 Q1	$3K	Buy	50 +35	+233%	+$1.73K	﹤0.01%	1861
2018 Q4	$1K	Hold	15	–	–	﹤0.01%	2053
2018 Q3	$1K	Buy	+15	New	+$1.08K	﹤0.01%	2183

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

SeaCrest Wealth Management's RGNX Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Regenxbio (RGNX) in Q3 2022, closing a stake of 835 shares — an estimated $21K sold.

SeaCrest Wealth Management first reported a position in RGNX in Q3 2018 and held it in 4 quarters. The position peaked at $21K in Q2 2022. 182 funds tracked by Wall St. Rank hold RGNX as of Q3 2022.

SeaCrest Wealth Management reported no remaining Regenxbio position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 835 Regenxbio shares in Q3 2022, an estimated $21K.
SeaCrest Wealth Management first reported a position in Regenxbio in Q3 2018 and held it in 4 quarters.
SeaCrest Wealth Management's Regenxbio position peaked at $21K in Q2 2022.
182 funds tracked by Wall St. Rank held Regenxbio as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.